Deferiprone, a generic version of Ferriprox® (Chiesi USA, Inc), has been made available by Taro Pharmaceutical Industries Ltd.
Deferiprone, an iron chelator, is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. The approval of the drug was based on a reduction in serum ferritin levels observed in clinical trials; there have been no controlled trials demonstrating a direct treatment benefit (ie, improvement in disease-related symptoms, functioning, or increased survival).
Deferiprone is supplied as 500mg tablets with functional scoring. The recommended dosage, which is calculated based on actual body weight, is administered orally 3 times per day.
The drug will be exclusively dispensed by BioPlus ®Specialty Pharmacy. Information on coverage and benefits, prior authorization, and co-pay assistance for patients with commercial insurance can be found here.
The safety and efficacy of deferiprone have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.
For more information visit tarocares.com.
Taro launches specialty generic Deferiprone Tablets, 500mg in the U.S. https://www.businesswire.com/news/home/20200928005649/en/Taro-Launches-Specialty-Generic-Deferiprone-Tablets-500mg-in-the-U.S. Accessed September 29, 2020.